Jingcheng Lyu1,2,#, Ruiyu Yue1,2,#, Ye Tian1,2,*, Boyu Yang1,2,*
Canadian Journal of Urology, Vol.33, No.2, pp. 361-375, 2026, DOI:10.32604/cju.2026.074814
- 20 April 2026
Abstract Objectives: Patients with a multi-parameter magnetic resonance imaging (mpMRI) prostate imaging report and data system (PI-RADS) score ≤ 3, but with clinically significant prostate cancer (CSPCa) detected by biopsy, are termed MRI-Invisible prostate cancer (MRI(-)PCa). This study aims to explore risk factors for MRI(-)PCa and identify immunohistochemical indicators with predictive significance. Methods: A retrospective analysis was conducted on 376 patients with PI-RADS score ≤ 3 who underwent 24-needle systematic prostate biopsy at Beijing Friendship Hospital, Capital Medical University (January 2015 to October 2025). Clinical data, imaging data, and Angiogenic factor with G and FHA domain… More >